

# Journal of Clinical Pathology



Cover legend: Upper panel: (A) Lymphoglandular complex like carcinoma, haphazard glands confined to lymphoid tissue. (B) Lymphoglandular complex like carcinoma, complex glands, gland angulation, single cells, stromal response. Lower panel: (A) Demonstrates an SSL-D (on the right) blending with a flatter, low-grade non-serrated epithelium (left). It should be noted that the lamina propria and muscularis mucosae are intact. Similarly, in (B) shows flat to undulating low-grade mucinous epithelium with intact lamina propria, reactive lymphoid follicles and retained muscularis propria. In both instances the dysplastic mucinous epithelium does not show serrations. Both these sessions should be designated as mucinous adenoma/'pre-LAMN'. LAMN, low-grade appendiceal mucinous neoplasms; SSL-D, sessile serrated lesions with dysplasia.

## Contents

### Gene of the month

- 435** *RB1*: governor of the cell cycle in health and disease—a primer for the practising pathologist  
*F Cordier, D Creytens*

### Best practice

- 439** Emerging and under-recognised patterns of colorectal carcinoma morphologies: a comprehensive review  
*Y Ono, O Yilmaz*

### Viewpoint

- 452** Serrated and mucinous appendiceal lesions: a viewpoint  
*R Chetty*

### Systematic review

- 457** *SMARCA4* alterations in non-small cell lung cancer: a systematic review and meta-analysis  
*D Wankhede, S Grover, P Hofman*

### Original research

- 464** Histopathology reporting of temporal artery biopsy specimens for giant cell arteritis: results of a modified Delphi study  
*D Taze, A Chakrabarty, R Venkateswaran, C Hartley, C Harden, A W Morgan, S L Mackie, K J Griffin*

- 471** Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPI) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy  
*S Jin, Z Shen, J Li, X Liu, Q Zhu, F Li, Y Shi, P Lin, X Xu, X Chen, X Geng, X Ding, H Liu*

## July 2024 Volume 77 Issue 7

**478**  
OPEN ACCESS

- In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study  
*F Pepe, E Guerini-Rocco, M Fassan, N Fusco, D Vacirca, A Ranghiero, K Venetis, A Rappa, S V Taormina, G Russo, E Rebellato, G Munari, A Moreno-Manuel, C De Angelis, C Zamagni, G Valabrega, U Malapelle, G Troncone, M Barberis, A Iaccarino*

**486**  
OPEN ACCESS

- Landscape of cancer biomarker testing in England following genomic services reconfiguration: insights from a nationwide pathologist survey  
*P Taniere, A G Nicholson, J R Gosney, M A Montero Fernandez, D Bury, D A Moore, E Verghese, I Soomro, L Joseph, N Bhatt, P Viola, R Bains, A G Lancot, J Ryan*

**495**

- Faecal immunochemical testing (FIT) in primary care: a follow-up service evaluation  
*R M Ayling, M Machesney*

### PostScript

- 500** Use of CD32, CD44 and CD71 to differentiate follicular lymphoma and diffuse large B-cell lymphoma subtypes by flow cytometry  
*L W Schwarz, J E Love, K N Nares, A Shamel, J R Fromm*

**502**

- International Delphi consensus on the histopathological diagnosis of adenomyosis  
*T McCaughey, S S Mooney, M Newman, L Constable, C Reddington, H C McNamara, M Healey*

### Short report

- 503** C3 concentrations can be normal in patients with C3 glomerulopathy secondary to C3 nephritic factor  
*H Anderson, M Van Voorthuizen, J O'Donnell, S Beck*



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://authors.bmj.com/open-access/>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org](http://www.publicationethics.org)



When you have finished with this please recycle it



The online version of this article contains multiple choice questions hosted on BMJ Learning.